About
About

Engitix is the first in the world to develop human liver, intestine and pancreatic ECM scaffolds for disease models in the field of drug discovery. Engitix has developed unique proprietary patented technologies allowing the development of human tissue-specific and disease-specific ECM scaffolds. Engitix 3D human ECM scaffolds represent the enabling tool for a better understanding of the ECM remodelling process in fibrotic diseases and solid tumors, with the consequent selection of more realistic targets for biomarkers and drug identification, development and validation within the same unique “all human” 3D model.

Provenance
Based on the pioneering academic research by Prof Pinzani and Dr Mazza’s team at University College London’s Institute for Liver and Digestive health.
Focus
Enabling target identification and drug development in liver fibrosis and gastro-intestinal solid tumors.
Meet the board
Proven, multi disciplined leadership team, with varied backgrounds including academia, the life sciences industry management consultancy and venture capital.
Board of Directors
Professor Massimo Pinzani
Co-Founder and Director
Prof. Pinzani is a pioneer in key areas of Hepatology such as the cellular and molecular mechanisms of fibrogenesis and the development of non-invasive diagnostic and prognostic tools for assessment of disease progression and regression in chronic liver diseases. In addition to clinical work, Massimo is Professor of Medicine and Director of the UCL Institute for Liver and Digestive Health at the Royal Free Hospital, London, and the Sheila Sherlock Chair of Hepatology at UCL. He has served on the governing and scientific boards of major international hepatology and gastroenterology organizations and as Associate Editor of peer-reviewed international medical journals. He is a member of advisory/scientific boards of several private companies and public institutions including the European Association for the Study of the Liver, where he serves as Educational Councilor. Since 2010 he has been a visiting professor at the Osaka City University Medical School in Japan.
Dr Giuseppe Mazza
Co-Founder and Chief Executive Officer
Giuseppe Mazza is a Post-Doctoral Fellow at the UCL Institute for Liver and Digestive Health. He joined the UCL Division of Medicine in 2013 and received his PhD in Tissue Engineering and Organ Regeneration. Dr Mazza pioneered the decellularisation procedure for whole human liver as well as the development of novel decellularisation procedures for small scale tissue scaffold development. He is currently responsible for Tissue Engineering and Regenerative Medicine at UCL, ILDH. Dr Mazza has been involved in several international healthcare organizations, and he founded the healthcare charity Associazione Icore ONLUS. He has been Director of R&D at Promethera Biosciences from 2015 to 2017.
Dr Steve Arlington
Chairman
Steve has considerable experience of working in and consulting to the pharmaceutical and biotech industries. He is well known to many executives in the top 20 Pharmaceutical Companies, and whilst partner at PwC, he launched the highly acclaimed Pharma 2020 series among other thought leadership points of view. Following a PhD in Immunopharmacology, Steve worked in R&D before joining PA Consulting Group, where he was Director of Healthcare, and subsequently PwC, where he became Lead Global Partner, Life Sciences and Pharmaceuticals. Steve was also Global Services Life Sciences Leader at IBM from 2002-2005. Steve has worked part-time since retirement from PwC in 2014, and is a visiting professor at UCL, a Fellow of the Royal Society of Medicine, and supports Genomics England, in addition to advising other businesses in the Life Sciences area.
David Dally
Chief Financial Officer
David Dally joined Singapore based MerLion Pharmaceuticals Pte Ltd in March 2007 as CFO and was appointed CEO in November 2013 Prior to MerLion, Mr. Dally was CFO at KuDOS Pharmaceuticals Ltd, an oncology drug discovery and development company in Cambridge, UK, which was sold to Astra Zeneca for $210m in 2005 and subsequently he held the CFO role at Rhytec Ltd, a medical devices company David qualified as a chartered accountant with Ernst and Young before he joined Amersham plc in 1991 where he held a number finance roles including Manager of Strategic Planning and VP Finance North America, managing the merger of Amersham Life Science with Pharmacia Biotech.
Stephen Brindle
Chief Operating Officer
For the last eight years Stephen was Managing Partner of Technikos LLP, an early stage venture capital fund with a long term commercial contract with Oxford University’s Bio-medical Engineering Department. Responsibilities included deal origination, due diligence, fund raising, board representation (either as an NED or Chairman), compliance, and LP reporting. Between 2011 and 2015 he also worked part time for a Technikos portfolio company in an operational capacity, helping the business grow from 3 to over 25 employees. At the time of leaving Technikos in July 2016, the fund comprised a portfolio of 15 companies (14 life sciences and one clean tech). Before Technikos LLP, Stephen spent 10 years in the City, as an institutional specialist salesman, focusing exclusively on the life sciences sector.